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Abstract The N-sarcoglycan (SG) gene is deleted in hamsters
with hereditary cardiomyopathies. Immunological analyses of
heart before, but not after, the progression of cardiomyopathy
(CM) revealed that the BIO 14.6 strain, a model of hypertrophic
CM, heterogeneously preserved K- and Q-SG with loss of L- and
N-SG. In contrast, the TO-2 strain, a model of dilated CM, did
not show either SG. Furthermore, in vivo transfer of the full
length N-SG gene to TO-2 hearts expressed all four SGs. Thus,
this age- and strain-dependent features suggest a more feasible
setting for TO-2 than BIO 14.6 to verify both CM progression
and the efficacy of gene therapy.
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1. Introduction
In spite of steady progress in cardiomyopathy (CM) ther-
apy, the prognosis of patients with CM is still poor and car-
diac transplantation is the most life-saving treatment for the
dilated CM (DCM) in the advances cases [1,2]. The animal
CM model is of great use for understanding the pathological
process [3] and developing a novel therapy in addition to
pharmacological intervention [4]. Gene supplementation will
be promising for the therapy of some types of CM caused by
gene deletion. The gene defect in N-sarcoglycan (SG) has been
identi¢ed to be responsible for both hypertrophic CM (HCM)
in the BIO 14.6 strain [5,6] and DCM in the TO-2 strain of
hamsters [5]. We have determined the breakpoint of the N-SG
gene of both strains [5]. The N-SG makes a complex with other
K-, L- and Q-SGs and connects dystrophin with the extracel-
lular matrix via K- and L-dystroglycan [7].
Compared with skeletal muscle of the BIO 14.6 strain where
all SG components were lost, the expression of these SGs has
only been elucidated in cardiac muscle in the advanced stage
of CM [5]. In addition, the SG expression was not su⁄ciently
characterized in the TO-2 strain. We have succeeded in an
e⁄cient gene transfer in vivo to hearts [8]. Based on these
backgrounds, we addressed the following questions: (i)
whether the loss of these SG proteins is commonly and simul-
taneously observed in these two strains and (ii) if full length N-
SG gene supplementation in vivo to the gene-deleted hearts is
actually capable of re-expression of all SGs in CM hearts.
2. Materials and methods
2.1. Experimental animals and preparation of speci¢c antibodies
To follow the time course of SG expression, we used 10 week old
male animals before the progression of myocardial degeneration [4],
because the SG expression was surveyed at the advanced stages [5].
Golden hamsters (normal controls, n = 20) were purchased from SLC
(Hamamatsu, Japan). The BIO 14.6 strain with clinical signs of HCM
followed by DCM (n = 15) and the TO-2 strain with signs of DCM
alone (n = 15) were purchased from Bio Breeders (Fitchburg, MA,
USA). We prepared polyclonal, site-directed antibody to N-SG of
which the epitope was selected following the speci¢c amino acid se-
quence deduced from the cloned cDNA and puri¢ed by an a⁄nity
chromatography [5]. Monoclonal antibodies to dystrophin, K-, L- and
Q-SG were obtained from Novocastra (UK) and polyclonal antibody
to L-galactosidase (L-Gal) was from Funakoshi (Tokyo, Japan).
2.2. In vivo gene transfection
The L-Gal gene with a CMV promoter at an XbaI site and a SV40
poly A signal at a BamHI site was inserted into a pBluescript II KA
(Stratagene, CA, USA) plasmid [8]. The full length N-SG gene with
SRK promoter was inserted between EcoRI and SpeI sites of the
plasmid pME18Sf.
HVJ-proteoliposomes were prepared as described earlier [8]. For
the in vivo gene transfer, the hamsters were anesthetized with pento-
barbital sodium (intraperitoneal, 50 mg/kg). Under open chest surgery
with constant volume ventilation (Harvard Model 683, South Natick,
MA, USA), the HVJ-proteoliposome (30 Wl) was injected into the left
ventricular free wall [9].
2.3. Immunological analyses
For the immunohistological identi¢cation of SG complex, obtained
hearts were ¢xed in 2% paraformaldehyde in saline (pH 7.4) and
treated as described earlier [9]. 4 Wm samples were sectioned from
frozen sample and stained by hematoxylin-eosin or speci¢c antibody
to L-Gal, K-SG, L-SG, Q-SG, N-SG or dystrophin. These sections were
incubated with each antibody (5 Wg/ml) overnight at 4‡C and then
with biotinylated goat anti-rabbit IgG for 20 min at 37‡C. The im-
munoproduct was visualized, using the peroxidase-labelled streptavi-
din-biotin complex method (HITOFINE SAB-PO kit, Nichirei, To-
kyo, Japan). After rinsing, the slides were counterstained with
Mayer’s hematoxylin solution and mounted for microscopy.
To verify e¡ective transfer of the L-Gal gene, histochemistry of the
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enzyme activity was intentionally replaced by the immunodetection of
L-Gal protein, because the blue color product to X-Gal reaction dis-
turbed the accurate detection of each SG. Moreover, the immuno-
staining of L-Gal protein was much more sensitive than L-Gal histo-
chemistry [9]. For these purposes, we employed adjacent serial
sections for the staining of dystrophin, each SG and L-Gal.
50 Wg protein from whole homogenates of the left ventricle in each
strain was subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane for
Western blot analysis. Target proteins were detected with the ECL
kit (Amersham Japan, Tokyo, Japan). For the in vivo gene trans-
fection, we employed the TO-2 strain, because the histological staining
of BIO 14.6 hearts demonstrated a diminished but signi¢cant preser-
vation of K- and Q-SG protein, while the TO-2 strain showed no SG
protein at the same age (see Section 3). The hamsters were killed on
day 7 when the L-Gal expression peaked after the in vivo transfection
[8].
3. Results and discussion
3.1. Immunohistology of cardiac muscles from normal, BIO
14.6 or TO-2 strains
Fig. 1 illustrates the typical examples of immunostaining of
dystrophin, K-, L-, Q- and N-SG of cardiac muscle from Gold-
en, BIO 14.6 and TO-2 hamsters. All four SGs were clearly
detected in sarcolemma of the Golden strain, revealing that
Fig. 1. Immunohistology for dystrophin (Dys), K-SG (K), L-SG (L), Q-SG (Q) and N-SG (N) in normal Golden (G), BIO 14.6 (B) and TO-2 (T)
hamster hearts at 10 weeks old (bar = 100 Wm; original magni¢cation, U200). Note that a trace but signi¢cant amount of K-SG and Q-SG are
detected, while both L-SG and N-SG were lost in BIO 14.6 and that all four SGs were completely missing in the TO-2 strain.
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employed antibodies selectively stained the SG proteins (G in
Fig. 1). The immunospeci¢city of each antibody was also
veri¢ed, because control non-immunized IgG did not stain
at all (data not shown).
Di¡erent from the previous reports on the advanced stage
of CM [5], cardiac muscle from CM hamster at the onset of
CM showed a clear contrast. In the BIO 14.6 myocardium,
both L- and N-SG proteins were missing, but K- and Q-SG were
weakly and heterogeneously expressed in cardiomyocytes (B
in Fig. 1). Closer inspection of the immunostaining showed
the deposition in sarcolemma facing the interstitial space but
not in those facing other cardiomyocytes. Furthermore, the
expression degree of immunoreactive K-SG was di¡erent from
animal to animal and from site to site even in the same heart.
Accordingly, these unequivocal results rendered us to decide
that the BIO 14.6 strain was not suitable for the exact iden-
ti¢cation of these SG proteins in heart.
In contrast, the TO-2 strain at the same age as other strains
revealed no immunodetection of all four SGs, including both
the K- and Q-SG (T in Fig. 1). Weak staining in capillary was
occasionally stained. The fact that N-SG was not immunohis-
tologically detected in BIO 14.6 and TO-2 strains matched
with the fact that the N-SG gene in both strains was deleted
at the 6.1 kb upstream of exon 2, lacking the promoter and
exon 1 [5]. In addition, dystrophin was clearly detected in all
three strains.
Fig. 2. Western blot analysis of K- and N-SG for left ventricles at 10
week old hamsters. A, B and C denote K-SG of Golden, BIO 14.6
and TO-2 strain hearts, respectively. D, E and F indicate N-SG of
Golden, BIO 14.6 and TO-2 strain hearts, respectively. Note that a
trace of K-SG was weakly but signi¢cantly detected in BIO 14.6 in
comparison with TO-2. MW shows the molecular weight of calibra-
tion proteins.
Fig. 3. Immunohistological identi¢cation of TO-2 heart co-transfected with both L-Gal and N-SG genes. L-Gal, K, L, Q, N and IgG denote im-
munostaining of L-Gal, K-SG, L-SG, Q-SG, N-SG and non-immunized IgG, respectively (bar = 100 Wm; original magni¢cation, U200).
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3.2. Immunoblotting of SGs in each strain
Samples for Western blotting of whole homogenates were
obtained from the left ventricle of Golden, BIO 14.6 and TO-
2 hamsters. Cardiac muscles of Golden hamsters revealed a
single band of both K- and N-SG (Fig. 2A,D), corresponding
to the molecular weight published before [5,10]. In BIO 14.6
hearts, a trace but signi¢cant amount of K-SG was detected,
indicating that a scarce amount of K-SG still existed at 10
weeks (Fig. 2B). In TO-2, no band corresponding to K-SG
was detected (Fig. 2C). Thus, TO-2 revealed a clear contrast
with normal or BIO 14.6, since it did not present any band
corresponding to K-SG at the same age. In addition, both BIO
14.6 and TO-2 demonstrated no N-SG band (Fig. 2E,F). These
results con¢rmed the immunohistological data described
above and our previous report [5].
3.3. Re-expression of SGs in TO-2 cardiomyocytes after
supplement of the normal gene
In TO-2 myocardium, all four SG proteins were missing in
contrast to BIO 14.6 myocardium. To evaluate whether nor-
mal N-SG gene supplementation to the targeted myocardial
cells in TO-2 hamsters restores the SG complex, we injected
the HVJ-proteoliposomes containing both full length N-SG
and L-Gal genes into TO-2 hamster heart. Fig. 3 summarizes
the result after gene transfection. At the maximum expression
period (on day 7) [8], the N-SG transgene product was clearly
expressed in myocardial cells. The L-Gal transgene product
was also con¢rmed in a serial section, showing the e⁄cient
co-transfection of both L-Gal and N-SG genes. In addition to
these transgene products, the K-, L- and Q-SG were distinctly
detected in the same site as L-Gal and N-SG. These immuno-
stainings were speci¢c to each protein, because non-immun-
ized IgG as the primary antibody did not stain the serial
section at all (IgG in Fig. 3). Accordingly, we conclude that
the re-expression of SG proteins was not originated from the
artifact during the gene transfer procedures.
It should be noted that the re-expression of these SG pro-
teins was not restricted to sarcolemma but the cytoplasm of
cardiomyocytes was also stained. The same phenomenon was
also reported after the gene transfer in skeletal muscle using
another vector [11,12]. These results might re£ect a compli-
cated protein tra⁄c after the biosynthesis of SGs. Glycopro-
teins would shift from ribosomes in the cytoplasm to the
Golgi apparatus to be glycosylated and subsequently incorpo-
rated into sarcolemma. Another explanation might be a
supranormal expression of SG proteins after the su⁄cient
gene delivery [12]. This idea was not likely, because not only
N-SG of which the gene was transfected but three other SGs
revealed the similar results.
When the L-Gal gene was solely injected to TO-2 hamster
heart, the L-Gal transgene product was exclusively detected in
cytoplasm of cardiomyocytes (data not shown). These results
indicate that L-Gal did not require the translocation after
biosynthesis.
3.4. Relation between SG disruption and cardiac failure
Dystrophin-associated glycoprotein complex (DAGC) is
made of four membrane spanning proteins (K-, L-, Q- and N-
SG) plus two integral proteins (K- and L-dystroglycan).
DAGC links the intracellular machinery, actin and the extra-
cellular matrix, laminin-2 [7]. A gene defect in these compo-
nents induces muscle degeneration and very often accompa-
nies cardiac symptoms. In human cases, gene mutation of
dystrophin, SGs and cardiac F-actin causes cardiac failure
with Duchenne or Becker muscular dystrophy [13], several
types of limb-girdle muscular dystrophy [13] and DCM [14],
respectively. At present, we do not know why K- and Q-SG
were better preserved in the BIO 14.6 strain than the TO-2
strain. The life expectancy of the BIO 14.6 strain is much
longer than the TO-2 strain [15] and this fact might be related
to the degree of SG loss.
Very recently, Bardor¡ et al. have reported that both dys-
trophin and K-SG were degraded in mice after infection of
enterovirus which has a protease 2A gene and that dystrophin
and K-SG were cleaved by the synthesized protease [16]. Thus,
the degradation of DAGC irrespective of di¡erent species
(mouse, hamster or human) or other etiologies (viral infection
or gene deletion) would be a reasonable scheme concerning
the pathogenesis of congestive heart failure in general.
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